4u Created
Image default
Business

U.S. appeals court vacates federal vaccine mandate pending additional hearing By Reuters



© Reuters. FILE PHOTO: A resident over 50 years old and immunocompromised receives a second booster shot of the coronavirus disease (COVID-19) vaccine in Waterford, Michigan, U.S., April 8, 2022. REUTERS/Emily Elconin

WASHINGTON (Reuters) – A U.S. appeals court panel said on Monday it would convene a full panel to reconsider President Joe Biden’s executive order requiring civilian federal employees to be vaccinated against COVID-19, and set aside the order pending that hearing.

The U.S. Court of Appeals for the Fifth Circuit, which is based in New Orleans, had reinstated the vaccine order in April by a 2-1 vote after it was blocked by a district court judge in January. [L2N2W530Z]

The court said on Monday that it would reconsider the case en banc, which means it will be heard by a larger panel of judges. No date was given for the hearing. Pending that hearing, the court said it would vacate the April ruling, which means that Biden’s order cannot be enforced.

Biden said in September he would require about 3.5 million government workers to get vaccinated by Nov. 22, barring a religious or medical accommodation, or face discipline or firing. Despite the legal fight, more than 90% of federal workers were vaccinated by December, the White House said last year.

The president’s vaccine and mask mandates have faced stiff opposition, led by Republicans, which have turned public safety measures endorsed by disease experts into a political and legal battle in the United States.

The United States passed the milestone of 1 million dead from the coronavirus in May. More than 250 people still die of the disease daily, according to the U.S. Centers for Disease Control and Prevention.



Source link

Related posts

XRP Climbs 10% In Bullish Trade By Investing.com

Sylvia Franklin

South Africa’s Ramaphosa to discuss climate change, energy transition with Biden By Reuters

Sylvia Franklin

Evercore on Ventyx Biosciences : 'Certainly expecting a strong move on Monday'

Sylvia Franklin